Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review article

Virus-like particle-based vaccines for animal viral infections

Elisa Crisci\textsuperscript{a}, Juan Bárcena\textsuperscript{b}, María Montoya\textsuperscript{a,c,*}

\textsuperscript{a} Centre de Recerca en Sanitat Animal (CReSA), UAB-IRTA, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
\textsuperscript{b} Centro de Investigación en Sanidad Animal (CISA-INIA), Madrid, Spain
\textsuperscript{c} Institut de Recerca i Tecnologia Agroalimentàries (IRTA), Barcelona, Spain

\textbf{A R T I C L E  I N F O}

Article history:
Received 14 June 2012
Accepted 20 August 2012
Available online 26 October 2012

Keywords:
Virus-like particles
Animal vaccines
Vaccine vectors

\textbf{A B S T R A C T}

Vaccination is considered one of the most effective ways to control pathogens and prevent diseases in humans as well as in the veterinary field. Traditional vaccines against animal viral diseases are based on inactivated or attenuated viruses, but new subunit vaccines are gaining attention from researchers in animal vaccinology. Among these, virus-like particles (VLPs) represent one of the most appealing approaches opening up interesting frontiers in animal vaccines. VLPs are robust protein scaffolds exhibiting well-defined geometry and uniformity that mimic the overall structure of the native virions but lack the viral genome. They are often antigenically indistinguishable from the virus from which they were derived and present important advantages in terms of safety. VLPs can stimulate strong humoral and cellular immune responses and have been shown to exhibit self-adjuvanting abilities. In addition to their suitability as a vaccine for the homologous virus from which they are derived, VLPs can also be used as vectors for the multimeric presentation of foreign antigens. VLPs have therefore shown dramatic effectiveness as candidate vaccines; nevertheless, only one veterinary VLP-base vaccine is licensed. Here, we review and examine in detail the current status of VLPs as a vaccine strategy in the veterinary field, and discuss the potential advantages and challenges of this technology.

© 2012 Sociedad Española de Inmunología. Published by Elsevier España, S.L. All rights reserved.

\textbf{Seudopartículas virales como vacunas víricas en veterinaria}

\textbf{R E S U M E N}

La vacunación constituye uno de los procedimientos más eficaces para controlar los patógenos y prevenir enfermedades tanto en seres humanos como en el campo veterinario. Las vacunas tradicionales frente a enfermedades animales se basan por lo general en la utilización de virus atenuados o inactivados. Sin embargo, las vacunas de subunidad están ganando terreno progresivamente en el campo de la sanidad animal. Entre ellas, las vacunas basadas en pseudopartículas virales o VLPs (por su nombre en inglés virus-like particles), representan una de las estrategias más atractivas actualmente en el campo de las vacunas para animales. Las VLPs son estructuras proteicas con una geometría y uniformidad muy definidas, que mimetizan la estructura de los virus nativos pero carecen de genoma viral.

* Corresponding author.
E-mail address: maria.montoya@cresa.uab.es (M. Montoya).

http://dx.doi.org/10.1016/j.inmuno.2012.08.002
Introduction

Vaccination is considered the most cost-effective way to control pathogens and prevent diseases both in human and veterinary field. Currently, the majority of licensed vaccines for animals are either live attenuated or killed, developed using conventional technologies. However, new subunit vaccines are getting a foothold in the veterinary vaccinology, and among these, virus-like particles (VLPs) represent one of the most appealing approaches, due to their intrinsic immunogenic properties as well as high safety profile, highlighted by several reviews appeared in the last ten years.

Virus-like particle-based vaccines

VLP vaccines combine many of the advantages of whole-virus vaccines and recombinant subunit vaccines, integrating key features that underlay their immunogenicity, safety and protective potential (Fig. 1): (a) particulate and multivalent nature, (b) well-defined geometry and remarkable uniformity with repetitive and ordered surface structures, (c) preservation of native antigenic conformation, (d) safety, as they are absolutely non-infectious and non replicating candidates, (e) higher stability than soluble antigens in extreme environmental conditions, (f) applicability as vectors for the presentation of foreign antigens, ligands or drugs, (g) amenability to fulfill the Differentiating Infected from Vaccinated Animals (DIVA)-compliance concerns.

VLPs are supramolecular assemblages with well-defined geometry, usually icosahedrons or rod-like structures, with diameters in the range of 25–100 nm that mimic the overall structure of the native virions. These protein cages are based on the natural intrinsic ability of many types of structural viral subunits, frequently major proteins in the capsid or envelope, to spontaneously self assemble into VLPs when expressed using recombinant expression systems. They are composed of multiple copies of one or more viral proteins and are usually antigenically indistinguishable from infectious virus or subviral particles.

The multivalent display and highly ordered structure of VLPs constitute pathogen-associated molecular pattern motifs (PAMPs). Since these motifs are, by and large, unique to microbial antigens, the mammalian immune system has

Fig. 1 – Immunogenic features of a VLP presenting foreign antigens. VLPs incorporate key features that underlay their immunogenicity, safety and vaccine potential: (a) well-defined geometry and remarkable uniformity with repetitive and ordered surface structures; multivalent display and highly ordered structure of VLPs constitute PAMP motifs common to many pathogens but not to the host that trigger innate immune sensing mechanism. PAMP can be recognized by TLRs and other PRRs which are present in the host cells; (b) preservation of native antigenic conformation; (c) particulate and multivalent nature; this feature means that VLPs are efficiently taken up by APCs. Their tendency to be a suitable size for uptake by DCs for processing and presentation by MHC-II and MHC-I (cross-presentation) pathways led to describe VLPs as “self-adjuvanting”; (d) safety for being non-infectious and non replicating candidates; VLPs lack the DNA or RNA genome of the virus altogether eliminate any of the risks associated with virus replication, reversion, recombination or re-assortment; (e) higher stability than soluble antigens in extreme environmental conditions; (f) applicability as carriers of foreign epitopes, drugs or for packaging PRR ligands; (g) possibility to follow the Differentiating Infected from Vaccinated Animals (DIVA)-compliance concerns. Figure created by Carla Martínez Castro and Elisa Crisci.
evolved to respond vigorously to this arrangement of antigens. PAMPs trigger the innate immune sensing mechanisms and can be recognized by Toll-like receptors (TLRs) as well as other pattern-recognition receptors (PRRs) which are present in host cells. In addition, due to their highly repetitive surface, VLPs have been shown to induce strong B cell responses by efficiently cross-linking the membrane-associated immunoglobulin molecules that constitute the B-cell receptor. The stimulation of B cells by VLPs is, in some instances, strong enough to elicit T cell-independent induction of IgM antibodies. Hence, there are examples of VLPs acting as T-cell independent B cell antigens. Besides, PAMPs can also stimulate antigen uptake by antigen presenting cells (APCs) and the subsequent presentation of antigens to cells of the adaptive immune response. Beyond the PAMPs property, their particulate nature and dimensions entail VLPs, but not their protein subunits, may be efficiently uptaken by APCs, in particular by dendritic cells (DCs). Uptake of antigens by APCs depends upon different properties, including size, shape, surface charge, etc., being the antigen size a key factor. APCs are able to uptake antigens with pathogen-like dimensions (20 nm to 3 μm) and it has been demonstrated that DCs optimally uptake antigens with diameters of approximately 40 nm, just within the range of VLPs’ size. The fact that VLPs present overall suitable characteristics for their uptake by DCs and subsequent processing and presentation by MHC-II and MHC-I (cross-presentation) pathways, led to describe VLPs as “self-adjuvanting” immunogen delivery systems. However, this statement should be tempered by the fact that some VLP-based candidate vaccines require formulation with potent adjuvants in order to induce efficient immune responses, indicating that the relative ability of diverse VLP types to induce the different branches of the immune response is influenced by a number of factors that are VLP-specific.

Overall, VLPs have been shown to stimulate strong B-cell-mediated immune responses and can be highly effective at stimulating CD4+ T cell proliferative responses and cytotoxic T lymphocyte (CTL) responses, the fundamental goal for any vaccine. The immune system has multiple mechanisms to robustly respond to virus particles, which may be exploited by VLP-based vaccines. In practical terms, this means that lower doses of antigen relative to monomeric antigen vaccines are sufficient to elicit a similar protective response. This consideration is particularly significant in the case of veterinary vaccines, where the cost of a vaccine must be weighed against the value of the vaccinated animal.

In terms of safety, the fact that VLPs lack any viral nucleic acid, completely abolishes any of the risks associated with virus replication, insertion, reversion, recombination or reassortment processes. VLP-based vaccines can be prepared without the need of propagating pathogenic viruses using different expression systems. Hence, the safety issues associated with whole-virus vaccine production and administration, relating to virus escape from production facilities, emergence of reversion mutants or effects in immunocompromised individuals, are obviated.

As has been previously reported, VLPs have been produced for a wide range of taxonomically and structurally distinct viruses that infect humans and other animals, as well as plant viruses. These comprise viruses that have a single capsid protein, multiple capsid proteins, and those with and without lipid envelopes, indicating that the ability to develop VLPs does not appear to be limited to any type of virus family or by the complexity of the virus particle. The VLPs derived from viruses with lipid envelopes, like influenza virus, are sometimes referred to as virosomes and consist of unilamellar like-lipoposomes carrying viral envelope proteins.

In addition to their suitability as a vaccine for the homologous virus from which they are derived, VLPs can also be used as platforms for inducing immune responses against antigens of choice, further enhancing and broadening their potential use both as prophylactic and therapeutic vaccines. The poor immune response of many soluble antigens can be overcome by rendering them highly repetitive in a single particle. This can be achieved by incorporating antigenic epitopes into VLPs by genetic fusion (chimeric VLPs) or by conjugating antigens to VLPs.

The development of recombinant DNA engineering techniques, combined with a wealth of high resolution viral structural information has facilitated the ability to modify VLPs deliberately, so that they can function essentially as molecular scaffolds for the presentation of genetically inserted foreign antigens. VLPs derived from both double- and single-stranded DNA and RNA viruses encompassing 14 different families of virus have been successfully used for the production of chimeric VLPs.

An alternative approach for displaying antigens on the surface of VLPs is the use of modular systems, in which the native VLP and the target antigen are synthesized separately and then conjugated in vitro covalently or non-covalently, linking the antigen to the surface of the preassembled VLPs. The conjugation techniques rely on the presence of addressable moieties on the surface of VLPs. If needed, VLPs can be engineered to contain useful attachment sites on the surface of the particles. An advantage of this approach is that the size and structure of the recombinant target antigens are not constrained by the requirements for correct folding of the VLP monomers and particle assembly. Chemical conjugation allows the attachment to VLPs of diverse kinds of target antigens: short linear peptides, cyclic peptides, full-length proteins, or nonprotein targets, such as glycans or smallhaptons. Moreover, the ability of VLPs to spontaneously assemble allows them to be disassembled and reassembled in vitro, a process which enables the incorporation of a different range of molecules within the VLP particles. For example, stimulators of innate immunity, such as TLR ligands can be packaged within VLPs. In this way the co-delivery of antigens and activators of innate immunity to DCs enables the subsequent induction of efficient T-cell responses, thus directing an adaptive immune response of appropriate magnitude, quality and specificity.

Another study highlighted the recent interest in developing VLPs from animal viruses as effective drug delivery system. Anticancer drug doxorubicin (DOX) was covalently conjugated to rotavirus-based VLPs (DVLPs) produced in Escherichia coli protein expression system. DVLPs were further linked with lactobionic acid (LA), a cellular targeting ligand which contains galactose (DVPLA), and intracellular uptake by different cells was examined. Zhao et al. demonstrated the release of DOX in
the cells with different kinetics and the lower toxicity of this system compared with free DOX.68

Not only can VLPs act as carriers of antigens derived from microbial pathogens (prophylactic vaccines) but they have also been successfully used to present self-antigens to the immune system, overcoming B-cell tolerance, thus opening the way for the development of therapeutic vaccines against chronic diseases, such as arthritis or Alzheimer’s disease, and cancer.1

Finally, the fact that VLPs do not contain non-structural viral proteins renders them compatible with DIVA strategies, as long as the structural proteins composing the VLPs are not being used as a marker. This represents an important potential for the use of VLP-based vaccines against notifiable diseases of livestock. The application of the DIVA technology allows compatibility between surveillance and vaccination programs, allowing vaccination to play a significant role in the control of these diseases.

Currently, VLP-based vaccines against human diseases are in various stages of development, spanning preclinical evaluation to market. Vaccines for hepatitis B (Recombivax® and Engerix®) and human papillomavirus (Gardasil® and Cervarix®) have been licensed commercially.55,49,50 Vaccines in clinical development include those of the type in which the VLP itself represents the target antigen and those in which the VLP is used to present foreign antigens to the immune system.10,31,35,42,51 Progresses have been made in developing VLP-based vaccines against hepatitis C virus, Ebola, Lassa virus, hantavirus, Marburg, SARS coronavirus and Chikungunya virus.7,3,28,52-55

Candidate virus-like particle-based vaccines for animal diseases

Animal virus-like particles as vaccine immunogens

Swine viruses and Paroviridae

In the veterinary field, although several candidate vaccines are in course of study (Table 1), only porcine circovirus type 2 (PCV2) VLP-based vaccine Porcilis PCV® (manufactured by Intervet International, The Netherlands), is licensed and commercially available.56 PCV2, a member of the Circoviridae family, is associated with post-weaning multisystemic wasting syndrome, a swine disease characterized by wasting, weight loss, respiratory distress and diarrhea that has a severe economic impact on production.57 The immunogen of Porcilis PCV® is the VLP formed by the ORF2 capsid protein of PCV2 produced using the baculovirus expression system. The vaccine is safe, highly immunogenic and effective against PCV2 infection. It has shown to induce humoral, cell-mediated immunity and protection against porcine circovirus-associated disease under field conditions after one intramuscular dose.58 Moreover, it induces broad immune protection against different genotypes (1 and 2) and various geographical isolates.59,60 For the same virus, another similar baculovirus expressed subunit vaccine, Ingelvac® CircoFLEX (Boehringer Ingelheim, Germany), has been licensed.61 It is also based on the expression of the ORF2 capsid protein but there is no information available whether the recombinant protein is assembled into VLPs.

Other swine viruses have been investigated as candidates for the development of VLP-based vaccines. One of the first studied ones was porcine parvovirus (PPV), a highly infectious virus causing reproductive failure in pigs. PPV-VLPs (VP2 protein) were tested in different animal models administered by a single intramuscular immunization coupled with different adjuvants. A microgram dose was highly immunogenic, very efficient in preventing transplacental virus transmission and gilts were protected against PPV-induced reproductive failure.62 Thus, Paroviridae has been shown to be a suitable virus family for the generation of VLP-based vaccines. Indeed, canine parvovirus (CPV) (VP2 protein), muscovy duck parvovirus (DPV) (VPs proteins), goose parvovirus (GPV) (VPs proteins) and mink enteritis virus (MEV) (VP2 protein) VLPs were also studied as vaccine candidates. In a recent preliminary study in geese, GPV-VLPs injected once subcutaneously have shown higher titers of neutralizing antibodies compared with inactivated and attenuated virus in vivo.63 Likewise, a previous study in ducks has also shown the production of specific DPV-antibodies after DPV-VLP immunization and the neutralizing antibody levels were consistent with those observed in ducklings inoculated with a commercial inactivated vaccine.64 Also, MEV-VLPs have shown to elicit higher antibody response after revaccination compared with a commercial conventional vaccine; interestingly, minks were protected against viral challenge and did not excrete MEV in feces.65 In addition, two studies used recombinant CPV-VLPs in a prime-boost strategy with adjuvant. Both tested VLPs were able to elicit neutralizing antibodies, sufficient to render all the immunized dogs protected against the viral challenge.66,67

Zoonotic viruses

Influenza virus is a zoonosis that remains one of the major threats to human health and involves a wide range of animal species, mainly avian, pigs and horses. Influenza-VLPs (FLU-VLPs) are assembled in producer cells infected by recombinant baculovirus and released into the culture medium mimicking the viral budding process. They are VLPs which incorporate the viral glycoproteins (hemaglutinin and neuraminidase) on the surface, and usually other viral structural proteins like the matrix protein M1, and the M2 ion channel protein.68 These FLU-VLPs demonstrated to provide protective immunity via either the intranasal or intramuscular route in the absence of adjuvants4 and have been exhaustively reviewed in.4,6,7,69 FLU-VLPs generated using the baculovirus expression system are now in clinical trials in humans93 (NCT01072799, NCT01014806, NCT00903552 and NCT00519389) [June 2012, ClinicalTrials.gov, A service of the US NIH, http://clinicaltrials.gov/] June 2012, Novavax, Research and Development, Clinical Trials, www.novavax.com/go.cfm?do=Page.View&pid=81].71 Additionally, a recent study has shown that pandemic H1N1 (2009) VLPs are immunogenic and provide protective immunity to pigs.72

Other VLP-based candidate vaccines produced against an important zoonotic agent are those derived from Rift valley fever virus (RVFV), a member of the Bunyaviridae family. RVFV is transmitted by several mosquito species and has a broad range of susceptible animal hosts.73 Interestingly, RVFV-VLPs (N, Gn, Gc) produced in mammalian cells were able to elicit
Table 1 – Virus-like particles as candidate vaccines in the veterinary field.

| Family/virus        | Content      | Development phase | Reference |
|---------------------|--------------|-------------------|-----------|
| Birnaviridae        | VP2, VPX, PP | + Animal          | 117       |
| Bunyaviridae        | N, GN, GC    | Animal            | 74        |
| Caliciviridae       | VP1          | Animal            | 105       |
| Caliciviridae       | VP60         | + Animal          | 101       |
| Circoviridae        | VP1, VP2     | + Animal          | 115       |
| Circoviridae        | ORF2 protein | + Licensed (Porcilis® PCV, Intervet) | 58–60 |
| Nodaviridae         | Coat protein | + Animal          | 120,121   |
| Orthomyxoviridae    | HÀ, NA, M1, M2 | Clinical trials | 70 and reviewed in 4,6,7,71 |
| Papillomaviridae    | L1, L2       | + Animal          | 87–90     |
| Paromyxoviridae     | NP, M, F, HN | Animal            | 71,118    |
| Paroviridae         | VP2          | + Animal          | 66,67     |
| Papillomavirus      | VP2          | + Animal          | 65        |
| Papillomavirus      | VP3          | + Animal          | 64        |
| Papillomavirus      | VP4          | + Animal          | 63        |
| Papillomavirus      | VP5          | + Animal          | 62        |
| Picornaviridae      | P1, 2A, 3C   | + Animal          | 113,157   |
| Enterovirus         | P1, 2A, 3C   | Animal            | 107       |
| FMDV                | P1, 2A, 3C   | Animal            | 108       |
| Reoviridae          | VP3          | + Animal          | 83,84     |
| Rotavirus           | VP3          | + Animal          | 77–80,158,159 |

* + indicate VLPs that protected the natural target host.

LCMV, lymphocytic choriomeningitis virus; IBDV, infectious bursal disease virus; RVFV, Rift valley fever virus; FCV, feline caliciavirus; RHDV, rabbit hemorrhagic disease virus; GAV, chicken anemia virus; PCV2, porcine circovirus type 2; HBV, hepatitis B virus; NNV, nervous necrosis virus; FLU, influenza virus; BPV, bovine papillomavirus; NDV, Newcastle disease virus; CPV, canine parvovirus; MEV, mink enteritis virus; DPV, muscovy duck parvovirus; GPV, goose parvovirus; PPV, porcine parvovirus; EMCV, porcine encephalomyocarditis virus; ERAV, equine rhinitis A virus; FMDV, foot and mouth disease virus; hamster PyV, hamster polyomaviruses; murine PyV, murine polyomaviruses; BTV, bluetongue virus; RV, rotavirus.

high titers of neutralizing antibodies and protected mice from a lethal challenge, abolishing virus replication.\(^\text{74}\)

**Reoviridae**

Rotaviruses (RV) form part of the Reoviridae family. These viruses are widespread among the newborn of many mammalian species, causing severe dehydration diarrhea.\(^\text{75}\) RV-VLPs expressing the main structural viral proteins (VPs: 2, 4, 6, 7) have been assessed for their efficacy using different animal models such as mice,\(^\text{76}\) rabbits,\(^\text{77}\) gnotobiotic piglets\(^\text{78}\) and cows.\(^\text{79}\) Using the parenteral route, RV-VLPs were proven to confer homologous protection in rabbits,\(^\text{77}\) and heterologous protection in mice.\(^\text{76}\) Moreover, homologous and heterologous VLPs were shown to be immunogenic in mice, where different levels of protection were reported depending on the dose, route or co-administration with adjuvants.\(^\text{80}\)

Other VLP-based candidate vaccines from this family are those generated from bluetongue virus (BTV). BT is a vector-borne disease of ruminants that causes hemorrhages and ulcers in the oral cavity and upper gastrointestinal tract.\(^\text{81}\) The immunogenicity of BTV-VLPs obtained from a baculovirus expression system developed for the simultaneous expression of all four major structural proteins (VP2, VP3, VP5, and VP7), has been reviewed recently in comparison with other BTV candidate vaccines.\(^\text{82}\) BTV-VLPs have been administered in the presence of various adjuvants to sheep, a vertebrate host susceptible to the virus. The results indicated that these multicomponent VLPs in conjunction with appropriate adjuvant elicited an immune response which protected against an infectious virus challenge.\(^\text{83}\) The combinations of different outer capsid proteins elicited higher neutralizing-antibody titers as compared to VP2 protein alone.\(^\text{84}\) Additionally, a
recent study has shown that the outer capsid is essential for complete protection, while the geographical origin of the BTV was not critical for the development of a serotype specific vaccine.85

**Papillomaviruses**

Papillomaviruses are important not only in human health, but also in the veterinary field. Indeed, horses, donkeys and cattle can develop local skin tumors termed sarcoids86 and dogs can present oral papillomas. A recent study has shown that intramuscular vaccination of horses with bovine papillomavirus (BPV-1) L1-VLPs results in a long-lasting antibody response against the virus. Neutralization titers were induced at levels that correlate with protection in both, experimental animals and man.87 Induction of a protective immune response was also previously reported in cattle (reviewed in Ref. 88), rabbits (cottontail rabbit papillomavirus, CRPV)89 and dogs (canine oral papillomavirus).90

**Caliciviridae**

Finally, another important virus family from which VLPs have been generated is Caliciviridae. Caliciviruses include important human and animal pathogens, classified into different genera. Noroviruses are the main cause of gastroenteritis in humans worldwide, and have also been described in livestock species, raising concerns regarding their zoonotic potential.91-93 Rabbit hemorrhagic disease virus (RHDV), the prototype strain of the genus Lagovirus, is the causative agent of an acute and highly contagious disease of rabbits which has decimated wild and domestic rabbit populations all over the world.94-96 Within the genus Vesivirus, feline calicivirus (FCV) causes respiratory illness in cats. In the last 10 years, there have been sporadic reports of highly virulent outbreaks of FCV disease in cats.97 Recombinant VLPs derived from the single capsid protein (VP1) of caliciviruses belonging to different genera, developed as candidate vaccines, have been reported. VLPs derived from human noroviruses have been used to induce systemic and mucosal immune responses in mice and are being evaluated in human clinical trials.98 Norovirus-derived VLPs have also been used to immunize calves and pigs, both inducing partial protection against a virus challenge.99,100 Better results have been obtained with VLP-based vaccine candidates for RHDV. RHDV-VLPs with adjuvant were injected once to rabbits at different days before lethal challenge. Such immunization was able to protect rabbits against a virulent challenge under the conditions used for commercial vaccine testing in France. Antibodies specific for the RHDV capsid protein could be detected as early as 5 days after vaccination, and the titers progressively increased over a 15-day period.101 Other authors have also reported complete protection of rabbits against a RHDV lethal challenge, induced by RHDV-VLPs.102-104 Similarly, FCV-VLPs have been tested in rabbits, which were immunized twice with VLPs and adjuvant. A measurable neutralizing antibody response was detected following the first immunization, which increased after boosting. Neutralizing antibody titers remained high throughout 3 months, and sera exhibited neutralizing activity against all the FCV strains analyzed.105

**Picornaviridae**

Viruses from the Picornaviridae family share a common replication strategy and the self-assembly of mature capsid proteins into VLPs. These properties have been shown for several picornaviruses, including equine rhinitis A virus (ERAV), foot and mouth disease virus (FMDV) and porcine encephalomyocarditis virus (EMCV). These VLPs were generated by co-expression of viral proteins (P1 polyprotein, the nonstructural protein 2A and protease 3C) using different expression systems: ERAV-VLPs were generated using a mammalian expression vector whereas the other VLPs were generated using the baculovirus expression system. ERAV is a respiratory pathogen of horses that may cause an acute febrile respiratory disease or subclinical infection.106 ERAV-VLPs were tested intramuscularly in mice with three doses followed by boost with UV-inactivated ERAV. The VLP-immunized animals showed significant titers of virus-neutralizing antibodies as well as the induction of a memory response to a neutralizing epitope.107 FMDV causes an economically important disease affecting pigs, cattle and other cloven-hoofed livestock. FMDV-VLPs were tested in guinea pigs. The animals were immunized twice with the VLPs and adjuvant. Both, FMDV-specific antibodies and neutralizing antibodies were generated in VLP-immunized animals, but their levels were lower than those induced by the conventional commercial vaccine.108 Probably, the poor results obtained with these and other FMDV-VLPs were due to their known low stability, which renders them notoriously difficult to obtain, usually with limited yields.109,110 EMCV causes myocarditis in preweaned pigs and severe reproductive failure in sowss111,112; EMCV-VLPs were tested in the natural host, inoculated once or twice using an adjuvant. The immunization elicited neutralizing antibody levels similar to those obtained after administration of the commercial vaccine. In this study, a prime-boost strategy was more effective than a single-dose immunization, in inducing the production and maintenance of neutralizing antibodies.113

**Poultry viruses**

Poultry industry is also another veterinary field searching for safe, immunogenic, protective and less expensive vaccines; hence, economically important avian viruses have been considered as potential targets for the development of subunit vaccines. Chicken anemia virus (CAV) belongs to the Circoviridae family and causes anemia and immunodeficiency in newly hatched chickens, with important economic losses.114 CAV VP1 and VP2 proteins expressed in insect cells were used to immunize chickens.115 Immunization with these proteins was able to elicit neutralizing antibodies and the progeny from immunized chicken was shown to be protected against challenge by CAV, directly after hatching.115 In this case the formation of CAV-VLPs was presumed but not confirmed.

Another important disease affecting chickens is caused by infectious bursal disease virus (IBDV), a Birnaviridae virus that induces immunosuppression by the destruction of immature B-lymphocytes within the bursa of Fabricus.116 Various IBDV-particles (VP2, VPX and PP), derived from a polyprotein differentially processed, were tested in chicken using one dose. The results established that all the IBDV-VLPs were effective at inducing humoral responses, but not all elicited the same virus-neutralizing capacity. They conferred protection
to all the vaccinated chickens, as did the commercial vaccine. No clear vaccine antigen dose-effect was observed.117

An interesting VLP-based vaccine candidate for poultry was reported recently.71 VLPs formed with structural proteins (NP, M, F, HN) of Newcastle disease virus (NDV), an avian enveloped paramyxovirus causing respiratory and/or nervous disease, were tested in a murine model in comparison with an UV-inactivated whole-virus vaccine. The VLPs demonstrated their effectiveness as immunogens. Levels of specific antibodies, characterized by ELISA, as well as neutralizing antibody titers resulting from NDV-VLP immunization were as high as or even higher than those resulting from immunization with the inactivated whole-virus vaccine, using comparable amounts of antigen. Furthermore, NDV-VLPs stimulated T-cell responses at levels slightly higher than those stimulated by the conventional vaccine.118 Another important finding was that NDV-VLPs can also be used as platforms to present peptide sequences from other target pathogens, but this topic will be commented in the next section.

Fish viruses
Viral fish diseases are also important in the veterinary field, since they create serious problems in pisciculture and seafood market, having a great economic impact. Nervous necrosis virus (NNV), from Nodaviridae family, causes encephalopathy and retinopathy in many species of fishes.119 VLPs derived from the single capsid protein of viruses belonging to the genus Betanodavirus, have been generated as vaccine candidates for different fish species. Two studies have shown that these VLPs were able to elicit neutralizing antibodies against NNV, and the responses were shown to be dose dependent.120,121 Additionally, Thiery et al. could demonstrate that vaccination with NNV-VLP was able to protect fish from a lethal challenge and to reduce virus spreading.120

Virus-like particles as platforms for foreign antigen delivery

As previously indicated, VLPs can also be used as platforms for the multimeric display of foreign antigens, that can be incorporated into VLPs either by genetic fusion or by chemical conjugation. In such cases VLPs serve both, as scaffolds for presenting antigens derived from other pathogens in a suitable repetitive configuration, and as adjuvants to boost the immune response. Ideally, the underlying immunogenic ‘viral fingerprints’ of VLPs are imparted to the attached antigens, making them as potent immunogens as VLPs themselves. In this section we will review VLPs derived from human or animal viruses used as vaccine vectors for presentation of antigens from viruses causing animal diseases (summarized in Table 2).

Hepadnaviridae
One of the first VLPs used as a vector to display foreign viral antigens was the one deriving from hepatitis B virus (HBV), which belongs to Hepadnaviridae family and is the causative agent of an important disease (cirrhosis and/or liver cancer) in humans. A neutralizing epitope derived from the VP1 protein of FMDV was fused to the HBV core antigen.
protein (HBcAg). The resulting chimeric VLPs elicited virus-neutralizing antibodies against FMDV, and induced a stronger immune response than the corresponding FMDV-peptide, in immunized guinea pigs. Furthermore, the chimeric VLPs were almost as immunogenic as inactivated FMDV particles, and VLP-immunized guinea pigs were completely protected against a challenge with FMDV. Several other studies have reported the generation of chimeric HBcAg-derived VLPs incorporating FMDV antigenic epitopes as vaccine candidates, using different approaches. Beesley et al. produced the chimeric VLPs using a yeast expression system, while Jin et al. used a system based on the transient expression of DNA plasmids in HeLa cell-cultures. The results obtained in these studies illustrate the potential utility of this vaccine strategy against FMDV. HBcAg-based VLPs were also used to express different epitopes (MHC-I or MHC-II restricted peptides) of lymphocytic choriomeningitis virus (LCMV), a rodent-borne virus. This study was performed in order to investigate if preexisting VLP-specific antibodies could interfere with specific cytotoxic T-cell and Th-cell responses, or with the induction of a protective response in mice. In this model, antigen presentation was not significantly affected either in vitro or in vivo by the presence of antibodies against the VLP scaffold, and protective immunity could be established in carrier-vaccinated animals. Thus, Ruedl et al. opened a new perspective around VLP vectors and the classical concept that previous immunization or maternal antibodies impair the induction of protective immune responses upon vaccination. Indeed, also in the veterinary field, the interference of colostral antibodies has been described in vaccinated animals. However, the results reported by Ruedl et al. suggest that preexisting VLP-specific antibodies are unlikely to be a limiting factor for VLP-based T-cell vaccines, although further studies need to be performed in veterinary species to fully clarify this aspect. Also, Storni et al. used HBcAg expressing a LCMV epitope to investigate the activation of APC for priming CTL responses after VLP vaccination. In this model they demonstrated that VLPs alone were inefficient at inducing CTL responses and failed to mediate effective protection form viral challenge, but they became very powerful if applied together with other substance that activated APCs (e.g., anti-CD40 antibodies or CpG).

A recent further confirmation of HBV as promising delivery vehicle has been published by Wang et al., using VLPs of HBc containing five mimotopes of IBDV. In this study chickens were immunized intramuscularly with four doses of HBc-SEPIS VLPs and the immunization with no adjuvant conferred protection against challenge by a virulent strain of IBDV.

**Polymaviridae**

VLPs derived from members of the Polymaviridae family are also amenable to be developed as vaccine vectors. Polyomaviruses (PyV) from different species have been used to display viral epitopes or tumor antigens. Hamster PyV-VLPs incorporating the GP33 CTL epitope derived from LCMV have shown to elicit specific protective memory CTL responses in vivo without adjuvant. Moreover, aggressive growth of tumors expressing GP33 was significantly delayed in these mice in vivo. Likewise, murine PyV-VLPs displaying the entire human prostate specific antigen (PSA) were used for immune therapy in a mouse model system. Eriksson et al. demonstrated that FSA-MPy-VLPs loaded onto DCs in the presence of CpG protected mice from tumor outgrowth, whereas the chimeric VLPs alone or without adjuvant only marginally protected the mice. Loading VLPs onto DCs opens a new perspective in the VLP-based vaccination. It reduces the anti-VLP antibody response, which is favorable for prime-boost therapies.

**Parvoviridae**

Parvovirus derived VLPs have also been used as scaffolds for foreign antigen presentation. Sedlik et al. generated recombinant PPV-VLPs incorporating a CD8+ CTL epitope from LCMV nucleoprotein. This epitope was fused to the N-terminus of VP2 capsid protein of PPV and the resulting chimeric VLPs were analyzed for their immunogenicity in mice. One intraperitoneal immunization with only 10 µg of PPV-LCMV-VLPs was able to induce complete protection of mice against a lethal LCMV challenge through the induction of virus-specific MHC-I-restricted CD8+ CTLs. The protection did not require CD4+ T helper function, neither adjuvant, and the strong in vivo CTL response induced by the chimeric VLPs persisted during months after immunization. PPV-VLPs have also been used to display immunoreactive epitopes derived from the PCV2 nucleoprotein, eliciting strong antibody responses in mice in absence of any adjuvant.

**Caliciviridae**

Another promising VLP system convenient for foreign antigen display is that based on RHDV-VLPs. Our group has identified three sites suitable for the insertion of heterologous immunogenic epitopes within the RHDV capsid protein. We generated recombinant chimeric RHDV-VLPs incorporating the MHC-I-restricted CD8+ T-cell epitope SIINFEKL, derived from chicken ovalbumin (OVA). The foreign epitope was inserted at two different locations (at the N-terminus and in a predicted exposed loop of the viral capsid protein) and the corresponding chimeric VLPs were tested for their immunogenicity in the mouse model. In vitro results showed that RHDV-VLPs activated DCs and these were able to process and present the foreign epitope for CD8+ specific recognition in a dose-dependent manner. In vivo, in the absence of adjuvant, those chimeric RHDV-VLPs were able to stimulate specific IFN-γ-producing cell priming and a powerful CTL response, mainly when the foreign epitope was inserted at N-terminus of the RHDV capsid protein. Mice immunized twice with the chimeric RHDV-VLPs were able to control an infection by a recombinant vaccinia virus expressing OVA in target organs. Similar results were reported by other group using RHDV-VLPs displaying the same OVA-derived epitope incorporated by chemical conjugation. In this study the conjugated RHDV-VLPs were administered with adjuvant (CpG) and tested for anti-tumor response in the mouse model. The results obtained indicated that the vaccination with the conjugated VLPs resulted in a significant reduction in tumor growth. Chimeric RHDV-VLPs have also been shown to be efficient vaccine vectors to immunize pigs, eliciting both, strong humoral and cellular responses against an inserted foreign epitope derived from FMDV. Another reported use of chimeric RHDV-VLPs was
as gene transfer vector. Chimeric RHDV-VLPs harboring DNA-binding sequences derived from human papillomavirus were able to package plasmid DNA and thus transfer genes into animal cells (Cos-7), opening the way for an alternative method for gene transfer.139

Paramyxoviridae

As mentioned in the previous section, NDV-VLPs (VLPs which contain M, NP, F and HN viral proteins) can also be used to display peptide sequences derived from target pathogens which are incorporated by genetic fusion either to terminal or cytoplasmic (CT) domains with the virus core proteins. The incorporation of a foreign glycoprotein ectodomain into NDV-VLPs can be achieved by generating a chimeric protein gene composed of sequences encoding the foreign protein ectodomain fused to those encoding the TM and CT domains of the appropriate NDV glycoprotein. Using this approach, the entire ectodomains of Nipah virus G, influenza virus and respiratory syncytial virus (RSV) were successfully inserted into NDV-VLPs.139 An interesting result was that immunization with NDV-VLPs containing the ectodomain of the RSV G protein provided complete protection from RSV replication in lungs, after intranasal challenge with live virus in the murine system.140 Furthermore, this approach would enable the incorporation into a single particle preparation of ectodomains derived from two different viruses,141 raising the possibility of using NDV-VLPs as a single vaccine against two different pathogens. For example, assembly of the NDV HN protein and the influenza HA protein into a single VLP could be used to protect chickens from both avian influenza and NDV, although such a divalent vaccine has not been reported yet.

Challenges for virus-like particle-based vaccine development

VLPs have been used as vaccines since the late 1980s.141 Despite this long history, to date only a handful of VLP-based vaccines is currently commercialized worldwide. Several other VLP-based vaccine candidates are undergoing clinical trials, but many others are still restricted to small-scale fundamental research, despite the accumulated evidence of the potential of VLPs as potent immunogens for many viral diseases of humans and animals. This limited availability is in part due to some technical and practical challenges associated to the large-scale VLP production process.

Although VLPs have been produced for a wide range of viruses, clearly not all are equally suitable for the development of vaccines. Even if proof-of-concept has been demonstrated with support from strong pre-clinical data, a VLP-based product candidate could not be developed as a vaccine for widespread use, if its manufacturing process is not scalable or cost-effective.142 VLPs made by the assembly of a single protein are usually able to be produced in large amounts and high quality, while structurally complex VLPs in some instances raise difficulties for large scale production.142 In addition, due to the inherent properties of the lipid envelope, production of enveloped VLPs is technically more complex.143 However, progresses are being made, and it is expected that in the near future the integration of process optimization tools (i.e., molecular biology, genetic engineering and systems biology), will overcome some of the current limitations affecting the large scale production of several types of VLPs.144

VLPs can be produced in different expression systems, including bacterial, yeast, mammalian or plant cells.145–147 However, the most popular choice is expression in insect cells using the recombinant baculovirus technology.32,34 This expression system has many advantages for VLP production (for recent reviews see 33, 51, 56, 143, 148). Large amounts of correctly folded recombinant proteins can be produced with eukaryotic-like post-translational modifications. Although yeast and bacteria cells can achieve similar yields, the complexity of the VLPs produced with the baculovirus expression system is remarkably higher (VLPs formed from up to five proteins). An additional advantage is that baculoviruses have a limited host range (namely for insects) and are hence safe for vertebrates. Insect cells to be used in the baculovirus expression system are derived from lepidopteran insects and are relatively easy to grow. They can grow in serum-free media and the cultures can easily be scaled up. The design of recombinant baculoviruses is simple and fast, providing a high versatility to this expression system. This is very important when producing vaccines for viruses whose surface proteins rapidly mutate (e.g., influenza A virus), a fundamental requirement to contend with potential pandemics in a timely manner. Nevertheless, this expression system presents important drawbacks. One of the main limitations is the significant coproduction of defective baculovirus particles, which are difficult to separate from VLPs. The baculovirus particles can interfere with the immunogenicity of the VLP-based vaccines.149 Furthermore, the potential contamination of VLP preparations with infective recombinant baculoviruses raises environmental concerns. For this reason, VLP-based immunogens produced in the baculovirus expression system must undergo either chemical inactivation treatments to eliminate baculovirus infectivity, that may impair the quality of the produced VLPs,150 or several downstream bioseparation processing steps that may increase final production costs.151 At this respect, a promising novel approach has been recently reported that might greatly simplify the downstream processing of biopharmaceuticals produced in insect cells.151 The new strategy is based on the use of recombinant baculoviruses lacking vp80 gene which is essential for virus formation, but does not affect foreign gene expression. The deletion is trans-complemented in a transgenic insect cell line used to generate the baculovirus seed stock, and the resulting defective baculoviruses can then be used to produce large amounts of recombinant proteins without contaminating virions.

The above mentioned problems have hampered for some time the development of vaccines produced in the insect cell manufacturing platform. However, the market authorization of two vaccines for veterinary applications (Porcilis® Pestil and Bayonac® CSF, against classic swine fever virus) in the year 2000,152 and afterwards the commercial licensing of the VLP-based vaccine Cervarix® for human use in 2007, were
critical milestones for the regulatory acceptance of insect cell technology in manufacturing of vaccines. Nowadays, this technology has been shown to meet the economical requirements for manufacturing modern vaccines for large populations, and is currently a dominant platform for the production of veterinary vaccines, thus, paving the way to the licensing of many other VLP-based vaccines for animal use.

Regarding the use of VLPs as foreign epitope display platforms, both strategies, the generation of chimeric VLPs by genetic fusion and the chemical conjugation of antigens to VLPs, pose some limitations. In order to induce high-titer antibody responses effectively, target antigens must be displayed on the surface of VLPs, in immunodominant regions, at a high density. Consequently, one of the key points for generating chimeric VLPs is the selection of suitable insertion sites, which must be present on the surface of the VLP and should not interfere with protein folding and assembly. However, generating chimeric VLPs is largely empirical; it is almost impossible to predict whether individual peptides will be compatible with VLP assembly or whether the insertions will be immunogenic. Another important limitation of the chimeric approach is that the size and nature of epitopes that can be inserted into VLPs, in particular into their immunodominant regions, is restricted. VLPs containing peptides longer than 20 amino acids often fail to assemble. Relatively large insertions have been successfully incorporated into VLPs, but these tend to be the exception more than the rule. These size limitations restrict the number of epitopes that can be targeted with an individual chimeric VLP. By contrast, the flexibility of the alternative approach based on the chemical conjugation of target antigens to previously assembled native VLPs offers substantial advantages, although it is dependent on the accessibility of addressable residues on both the VLP and the target antigen. On the other hand, from a manufacturing standpoint, the genetic fusion approach may have advantages over chemical conjugation, since chimeric VLPs can be produced and purified using the same well-established methods used to purify unmodified parental VLPs, whereas the production process of conjugated VLPs entails extra challenges and the quality control methods are inevitably more complex.

VLP foreign epitope display strategies typically only permit epitopes of a limited size to be targeted. Since pathogens usually undergo antigenic variation in response to host immune pressures, vaccines based on VLPs displaying foreign epitopes will only be effective against highly conserved B- or T-cell epitopes. Consequently, VLPs appear best suited to target highly conserved antigens. An example of such an appropriate target is the 23-amino acid extracellular domain of M2 protein from influenza A virus, which is highly conserved among viral strains, and has been shown to induce protection in mice against a lethal challenge, upon administration as a peptide incorporated on HBV-derived VLPs.

As indicated in previous sections, the relative ability of diverse VLP types to induce the different branches of the immune response is influenced by a number of factors that are VLP-specific. Therefore, it appears unlikely that a single VLP platform will meet all the desired requirements. However, the continued parallel development of multiple VLP platforms will ensure that individual vaccines can be tailored appropriately to the type of immune response required in each case.

**Conclusions**

VLPs are appealing as vaccine candidates because their inherent properties (i.e., multimeric antigens, particulate structure, not infectious) are suitable for the induction of safe and efficient humoral and cellular immune responses. The fact the VLP-based vaccines may comply with the DIVA requirements, make them even more attractive for vaccine development in the veterinary field. Currently, there is a clear trend toward the establishment of VLPs as a powerful tool for vaccine development. In the human vaccines market, five are already VLP-based: three for HBV and two for HPV, while in the veterinary field, a VLP-based vaccine against PCV2 has recently been licensed. Several VLP vaccine candidates targeting human and animal diseases are currently in late stages of evaluation. Moreover, the development of VLPs as platforms for foreign antigen display has further broadened their potential applicability both as prophylactic and therapeutic vaccines.

As with all new approaches, there are still challenges to overcome related with manufacturing processes, or with the generation of chimeric VLPs. Recent results in these areas are, however, very encouraging and underscore the versatility of the VLP-based technology and its applicability for the development of new generation vaccines.

**Conflict of interests**

The authors declare no financial conflict of interests.

**Acknowledgements**

We thank Carla Martínez Castro for providing the image in Fig. 1. We would like to acknowledge Lorenzo Fraile for his collaboration and critical reading of the manuscript.

Our work in this field was partially funded by grants from the Spanish Ministry of Science and Innovation: AGL2006-13809-C02, AGL2009-12945-C02, AGL2010-22200-C02, CSD 2006-00007 (FORCIVIR, program CONSOLIDER-INGENIO 2010), and EU: NADIR-UE-228394.

**References**

1. Jennings GT, Bachmann MF. The coming of age of virus-like particle vaccines. Biol Chem. 2008;389:521–36.
2. Liu F, Ge S, Li L, Wu X, Liu Z, Wang Z. Virus-like particles: potential veterinary vaccine immunogens. Res Vet Sci. 2012;93:553–9.
3. Plummer EM, Manchester M. Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011;3:174–96.
4. D’Aoust MA, Couture MM, Charland N, Trepanier S, Landry N, Ore F, et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J. 2010;8:607–19.
5. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10:787–96.

6. Kang SM, Song JM, Quan FS, Companis RW. Influenza vaccines based on virus-like particles. Virus Res. 2009;143:140–6.

7. Haynes JR. Influenza virus-like particle vaccines. Expert Rev Vaccines. 2009;8:435–45.

8. Roy P, Noad R. Virus-like particles as a vaccine delivery system: myths and facts. Hum Vaccin. 2008;4:5–12.

9. Ludwig C, Wagner R. Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol. 2007;18:537–45.

10. Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. Methods. 2006;40:60–5.

11. Noad R, Roy P. Virus-like particles as immunogens. Trends Microbiol. 2003;11:438–44.

12. Douglas T, Young M. Viruses: making friends with old foes. Science. 2006;312:873–5.

13. Garcea RL, Gissmann L. Virus-like particles as vaccines and vessels for the delivery of small molecules. Curr Opin Biotechnol. 2004;15:513–7.

14. Johnson JE, Chiu W. Structures of virus and virus-like particles. Curr Opin Struct Biol. 2000;10:229–35.

15. Bachmann MF, Zinkernagel RM. Neutralizing antiviral B cell responses. Annu Rev Immunol. 1997;15:235–70.

16. Kouskoff V, Laaca G, Nemazee D. T cell-independent rescue of B lymphocytes from peripheral immune tolerance. Science. 2000;287:2501–3.

17. Chackerian B, Lowy DR, Schiller JT. Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc Natl Acad Sci U S A. 1999;96:2373–8.

18. Bachmann MF, Rohrer UH, Kundig TM, Burki K, Hengartner H, Zinkernagel RM. The influence of antigen organization on B cell responsiveness. Science. 1993;262:1448–51.

19. Fehr T, Skrastina D, Pumpens P, Zinkernagel RM. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Proc Natl Acad Sci U S A. 1998;95:9477–81.

20. Scheerlinck JP, Greenwood DL. Particulate delivery systems for animal vaccines. Methods. 2006;40:118–24.

21. Füchs T, Gamvrellis A, Crimeen-Irwin B, Pietersz GA, Li J, Mottram PL, et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol. 2004;173:3148–54.

22. Xiang SD, Scholzen A, Minigo G, David C, Apostolopoulos V, Mottram PL, et al. Pathogen recognition and development of particulate vaccines: does size matter? Methods. 2006;40:1–9.

23. Liu WJ, Liu XS, Zhao KN, Leggatt GR, Frazer IH. Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell agonist. Virology. 2000;273:374–82.

24. Yan M, Peng J, Jabbar IA, Liu X, Filgueira I, Frazer IH, et al. Despite differences between dendritic cells and Langerhans cells in the mechanism of papillomavirus-like particle antigen uptake, both cells cross-prime T cells. Virology. 2004;324:297–310.

25. Goldmann C, Petry H, Fyre S, Ast O, Ebitis S, Jentsch KD, et al. Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies. J Virol. 1999;73:4465–9.

26. Gedvilaité A, Dorn DC, Sasaunauskas K, Pecher G, Bulvaita E, Lawatscheck R, et al. Virus-like particles derived from major capsid protein VP1 of different polyomaviruses differ in their ability to induce maturation in human dendritic cells. Virology. 2006;354:252–60.

27. Tissot AC, Renhofa R, Schmitz N, Cielens I, Meijerink E, Ose V, et al. Versatile virus-like particle carrier for epitope based vaccines. PLoS One. 2010;5:e9809.

28. Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci U S A. 2003;100:6753–8.

29. Paliard X, Liu Y, Wagner R, Wolf H, Baenziger J, Walker CM. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res Hum Retroviruses. 2000;16:273–82.

30. Schirmbeck R, Bohm W, Reimann J. Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen. Intervirology. 1996;39:111–9.

31. Spohr G, Bachmann MF. Exploiting viral properties for the rational design of modern vaccines. Expert Rev Vaccines. 2008;7:43–54.

32. Rollod A, Meliando MC, Castilho LR, Carrondo MJ, Alves PM. Virus-like particles in vaccine development. Expert Rev Vaccines. 2010;9:119–76.

33. Vicente T, Roldao A, Peixoto C, Carrondo MJ, Alves PM. Large-scale production and purification of VLP-based vaccines. J Invertebr Pathol. 2013;107 Suppl.1:S42–8.

34. Roy P, Noad R. Virus-like particles as a vaccine delivery system: myths and facts. Adv Exp Med Biol. 2009;655:145–58.

35. Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines. 2007;6:381–90.

36. Conner ME, Estes MK. Virus-like particle vaccines. In: Levine MM, Kaper JB, Rapuoli R, Liu MA, Good MF, editors. New generation vaccines. 3rd ed. New York and Basel: Informa Healthcare; 2004. p. 283–93.

37. Casal JI. Use of the baculovirus expression system for the generation of virus-like particles. Biotechnol Genet Eng Rev. 2001;18:73–87.

38. Bragard C, Duncan GH, Wesley SV, Naidu RA, Mayo MA. Virus-like particles assemble in plants and bacteria expressing the coat protein gene of Indian peanut clump virus. J Gen Virol. 2000;81:267–72.

39. Jagadish MN, Edwards SJ, Hayden MB, Grusovin J, Vandenberg K, Schoofs P, et al. Chimimetic potyvirus-like particles as vaccine carriers. Intervirology. 1996;39:85–92.

40. Lacasse P, Denis J, Lapointe R, Leclerc D, Lamarre A. Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation. J Virol. 2008;82:785–94.

41. Wilschut J. Influenza vaccines: the virome concept. Immunol Lett. 2009;122:118–21.

42. Bachmann MF, Jennings GT. Virus-like particles: combining innate and adaptive immunity for effective vaccination. In: Stefan HEK, editor. Novel vaccination strategies. Weinheim: Wiley-VCH Verlag GmbH & Co.; 2004. p. 415–32.

43. Jegerlehner A, Tissot A, Lechner F, Seppel P, Erdmann I, Kundig T, et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine. 2002;20:3104–12.

44. Mateu MG. Virus engineering: functionalization and stabilization. Protein Eng Des Sel. 2011;24:53–63.

45. Strable F, Finn MG. Chemical modification of viruses and virus-like particles. Curr Top Microbiol Immunol. 2009;327:1–21.

46. Raja KS, Wang Q, Gonzalez MJ, Manchester M, Johnson JE, Finn MG. Hybrid virus-polymer materials: 1. Synthesis and properties of PEG-decorated cowpea mosaic virus. Biomacromolecules. 2003;4:472–6.
virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol. 2004;172:1777–85.

48. Zhao Q, Chen W, Chen Y, Zhang L, Zhang J, Zhang Z. Self-assembled virus-like particles from rotavirus structural protein VP6 for targeted drug delivery. Bioconjug Chem. 2011;22:346–52.

49. Monie A, Hung CF, Roden R, Wu TC. Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics. 2008;2:97–105.

50. Shi L, Sings HL, Bryan JT, Wang B, Wang Y, Mach H, et al. GARDASIL: prophylactic human papillomavirus vaccine development – from bench top to bed-side. Clin Pharmacol Ther. 2007;81:259–64.

51. Roldao A, Silva AC, Mellado MCM, Alves PM, Carrondo MJT. Viruses and virus-like particles in biotechnology: fundamentals and applications. In: Murray M-Y, editor. Comprehensive biotechnology. 2nd ed. Burlington: Academic Press; 2011. p. 625–49.

52. Branco LM, Grove JN, Geske FJ, Boisen ML, Muncy JJ, Magliato SA, et al. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. Virol J. 2010;7:279.

53. Li C, Liu F, Liang M, Zhang Q, Wang X, Wang T, et al. Hantavirus-like particles generated in CHO cells induce specific immune responses in C57BL/6 mice. Vaccine. 2010;28:4294–300.

54. Warfield KL, Aman MJ. Advances in virus-like particle vaccines for flaviviruses. J Infect Dis. 2011;204 Suppl. 3: S1053–9.

55. Garrone P, Fluckiger AC, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, Manicj J, et al. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med. 2013;5:201ra371.

56. Mena JA, Kamen AA. Insect cell technology is a versatile and robust vaccine manufacturing platform. Expert Rev Vaccines. 2011;10:1063–81.

57. Segales J, Domingo M. Postweaning multisystemic wasting syndrome (PMWS) in pigs. A review. Vet Q. 2002;24:109–24.

58. Martelli P, Ferrari L, Morganti M, De Angelis E, Bonilauri P, Guazzetti S, et al. One dose of a porcine circovirus 2 subunit vaccine induces humoral and cell-mediated immunity and protects against porcine circovirus-associated disease under field conditions. Vet Microbiol. 2011;149:339–51.

59. Fort M, Sibila M, Allepuz A, Mateu E, Roerink F, Segales J. Porcine circovirus type 2 (PCV2) vaccination of conventional pigs prevents viremia against PCV2 isolates of different genotypes and geographic origins. Vaccine. 2008;26: 1063–71.

60. Fort M, Sibila M, Perez-Martín E, Nofrarias M, Mateu E, Segales J. One dose of a porcine circovirus 2 (PCV2) sub-unit vaccine administered to 3-week-old conventional piglets elicits cell-mediated immunity and significantly reduces PCV2 viremia in an experimental model. Vaccine. 2009;27:4031–7.

61. Fachinger V, Bischoff R, Jedidia SB, Saalmuller A, Elbers K. The effect of vaccination against porcine circovirus type 2 in pigs suffering from porcine respiratory disease complex. Vaccine. 2008;26:1488–99.

62. Antonis AF, Brusche C, Rueda P, Maranga L, Casal JI, Vela C, et al. A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure. Vaccine. 2006;24:5481–90.

63. Ju H, Wei N, Wang Q, Wang C, Jing Z, Guo L, et al. Goose parvovirus structural proteins expressed by recombinant baculoviruses self-assemble into virus-like particles with strong immunogenicity in goose. Biochem Biophys Res Commun. 2011;409:131–6.

64. Le Gall-Recule G, Jestin V, Chagnaud P, Blanchard P, Jestin A. Expression of muscovy duck parovirus capsid proteins (VP2 and VP3) in a baculovirus expression system and demonstration of immunity induced by the recombinant proteins. J Gen Virol. 1996;77 Pt 9:2159–63.

65. Christensen J, Alexandersens S, Bloch B, Aasted B, Uttenthal A. Production of mink enteritis parovirus empty capsids by expression in a baculovirus vector system: a recombinant vaccine for mink enteritis parovirus in mink. J Gen Virol. 1994;75 Pt 1:149–55.

66. Lopez de Turiso JA, Cortes E, Martinez C, Ruiz de Ybanez R, Simarro I, Vela C, et al. Recombinant vaccine for canine parovirus in dogs. J Virol. 1992;66:2748–53.

67. Saliki JT, Mizak B, Flore HP, Gettig RR, Burand JP, Carmichael LE, et al. Canine parovirus empty capsids produced by expression in a baculovirus vector: use in analysis of viral properties and immunization of dogs. J Gen Virol. 1992;73 Pt 2:369–74.

68. Bruin A, Barcena J, Blanco E, Borrego B, Dory D, Escribano JM, et al. Current strategies for subunit and genetic viral veterinary vaccine development. Virus Res. 2011;157:1–12.

69. Kang SM, Pushko P, Bright RA, Smith G, Compaan RW. Influenza virus-like particles as pandemic vaccines. Curr Top Microbiol Immunol. 2009;333:269–89.

70. Lopez-Macias C, Ferat-Osorio E, Tenorio-Calvo A, Isibasi A, Talavera J, Arteaga-Ruiz O, et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine. 2011;29:7826–34.

71. Morrison TG. Newcastle disease virus-like particles as a platform for the development of vaccines for human and agricultural pathogens. Future Virol. 2010;5:545–54.

72. Pyo HM, Masic A, Woldeab N, Embury-Hyatt C, Lin L, Shin YK, et al. Pandemic H1N1 influenza virus-like particles are immunogenic and provide protective immunity to pigs. Vaccine. 2012;30:1297–304.

73. Fick R, Bouloy M. Rift valley fever virus. Curr Mol Med. 2005;5:827–34.

74. Naslund J, Lagerqvist N, Habjan M, Lundkvist A, Evander M, Ahlm C, et al. Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus. Virology. 2009;385:409–15.

75. Bishop RF. Natural history of human rotavirus infection. Arch Pediatr Adolesc Med. 1995;149:119–28.

76. Jiang B, Estes MK, Barone C, Barniak V, O’Neal CM, Ottaviano A, et al. Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles. Vaccine. 1999;17:1005–13.

77. Conner ME, Crawford SE, Barone C, Estes MK. Rotavirus vaccine administered parenterally induces protective immunity. J Virol. 1993;67:6633–41.

78. Yuan L, Geyer A, Hodgins DC, Fan Z, Qian Y, Chang KO, et al. Intranasal administration of 2/6-rotavirus-like particles with mutant Escherichia coli heat-labile toxin (LT-R192G) induces antibody-secreting cell responses but not protective immunity in gnotobiotic pigs. J Virol. 2000;74:8843–53.

79. Fernandez FM, Conner ME, Hodgins DC, Parwani AV, Nielsen PR, Crawford SE, et al. Passive immunity to bovine rotavirus in newborn calves fed colostrum supplements from cows immunized with recombinant SA11 rotavirus core-like particle (CLP) or virus-like particle (VLP) vaccines. Vaccine. 1998;16:507–16.
baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. Vaccine. 2003;21:3895–900.
81. Maclellan NJ, Drew CP, Darpel KE, Worwa G. The pathology and pathogenesis of bluetongue. J Comp Pathol. 2009;141:1–16.
82. Niedbalski W. Bluetongue vaccines in Europe. Pol J Vet Sci. 2011;14:299–304.
83. Roy P, French T, Erasmus BJ. Protective efficacy of virus-like particles for bluetongue disease. Vaccine. 1992;10:28–32.
84. Roy P, Urakawa T, Van Dijk AA, Erasmus BJ. Recombinant virus vaccine for bluetongue disease in sheep. J Virol. 1990;64:1998–2003.
85. Stewart M, Doyas CJ, Chatzinasiou E, Athmaram TN, Papanastassopoulou M, Papadopoulos Q, et al. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection. Vaccine. 2012;30:2131–9.
86. Nasir L, Campo MS. Bovine papillomaviruses: their role in the aetiology of cutaneous tumours of boids and equids. Vet Dermatol. 2008;19:243–54.
87. Hainisch EK, Brandt S, Shafti-Keramat S, Van den Hoven R, Kirnbauer R. Safety and immunogenicity of BPV-1 L1 virus-like particles in a dose-excitation vaccination trial in horses. Equine Vet J. 2011;44:107–11.
88. Campo MS. Vaccination against papillomavirus in cattle. Clin Dermatol. 1997;15:275–83.
89. Breithardt F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol. 1995;69:3595–63.
90. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A. 1995;92:11553–7.
91. Bank-Wolf BR, Konig M, Thiel HJ. Zoonotic aspects of infections with noroviruses and sapoviruses. Vet Microbiol. 2010;140:204–12.
92. Almanza H, Cubillos C, Angulo I, Mateos F, Caston JR, van der Poel WH, et al. Self-assembly of the recombinant capsid protein of a swine norovirus into virus-like particles and evaluation of monoclonal antibodies cross-reactive with a human strain from genogroup II. J Clin Microbiol. 2008;46:3971–9.
93. Wang QH, Han MG, Cheetham S, Souza M, Funk JA, Saif LJ. Porcine noroviruses related to human noroviruses. Emerg Infect Dis. 2005;11:1874–81.
94. Angulo E, Barcena J. Towards a unique and transmissible vaccine against myxomatosis and rabbit haemorrhagic disease for rabbit populations. Wildl Res. 2007;34:567–77.
95. Cooke BD. Rabbit haemorrhagic disease: field epidemiology and the management of wild rabbit populations. Rev Sci Tech. 2002;21:347–58.
96. Luque D, Gonzalez JM, Gomez-Blanco J, Marabini R, Chichon J, Menas J, et al. Epitope insertion at the N-terminal molecular switch of the rabbit hemorrhagic disease virus t = 3 capsid protein leads to larger t = 4 capsids. J Virol. 2012;86:6470–80.
97. Coyne KP, Jones BR, Kipar A, Chantrey J, Porter CJ, Barber PJ, et al. Lethal outbreak of disease associated with feline calcivirus infection in cats. Vet Rec. 2006;158:544–50.
98. Tacket CO, Shtein MB, Losonsky GA, Wasserman SS, Estes MK. Humoral, mucosal, and cellular immune responses and oral Norwalk virus-like particles in volunteers. Clin Immunol. 2003;108:241–7.
99. Souza M, Costantini V, Azevedo MS, Saif LJ. A human norovirus-like particle vaccine adjuvanted with ISCOM or mLT induces cytokine and antibody responses and protection to the homologous GII.4 human norovirus in a gnotobiotic pig disease model. Vaccine. 2007;25:8448–59.
100. Han MG, Cheetham S, Azevedo M, Thomas C, Saif LJ. Immune responses to bovine norovirus-like particles with various adjuvants and analysis of protection in gnotobiotic calves. Vaccine. 2006;24:317–26.
101. Laurent S, Vautherot JF, Madelaine MF, Le Gall G, Rasschaert D. Recombinant rabbit hemorrhagic disease virus capsid protein expressed in baculovirus self-assembles into viruslike particles and induces protection. J Virol. 1994;68:6794–8.
102. Perez-Filgueira DM, Resino-Talavan P, Cubillos C, Angulo I, Barderas MG, Barcena J, et al. Development of a low-cost, insect larvae-derived recombinant subunit vaccine against RHDV. Virology. 2007;364:422–30.
103. Plana-Duran J, Bastons M, Rodriguez MJ, Climent I, Cortes E, Vela C, et al. Oral immunization of rabbits with VP60 particles confers protection against rabbit hemorrhagic disease. Arch Virol. 1996;141:1423–36.
104. Nagasea HS, Wang LF, Hyatt AD, Morrissy CJ, Lenghaus C, Westbury HA. Self-assembly, antigenicity, and immunogenicity of the rabbit hemorrhagic disease virus (Czechoslovakian strain V-351) capsid protein expressed in baculovirus. Arch Virol. 1995;140:1095–108.
105. Di Martino B, Marsillo F, Roy P. Assembly of feline calcivirus-like particle and its immunogenicity. Vet Microbiol. 2007;120:173–8.
106. Li F, Drummer HE, Ficorilli N, Studdert MJ, Crabb BS. Identification of noncytopathic echovirus 1 as a cause of acute febrile respiratory disease in horses. J Clin Microbiol. 1997;35:937–43.
107. Lynch SE, Gilkerson JR, Symes SJ, Huang JA, Tataczczuk L, Hartley CA. Equine rhinitis A virus-like particle expressing RNA vaccine induces a virus neutralising immune response in mice. Virus Res. 2011;158:294–7.
108. Cao Y, Lu Z, Sun J, Bai X, Sun P, Bao H, et al. Synthesis of empty capsid-like particles of Asia I foot-and-mouth disease virus in insect cells and their immunogenicity in guinea pigs. Vet Microbiol. 2009;137:10–7.
109. Abrams CC, King AM, Belsham GJ. Assembly of foot-and-mouth disease virus empty capsids synthesized by a vaccinia virus expression system. J Gen Virol. 1995;76 Pt 12:3089–99.
110. Lewis SA, Morgan DO, Grubman MJ. Expression, processing, and assembly of foot-and-mouth disease virus capsid structures in heterologous systems: induction of a neutralizing antibody response in guinea pigs. J Virol. 1991;65:6752–80.
111. Gelmetti D, Meroni A, Brocchi E, Koenen F, Cammarata G. Pathogenesis of encephalomyocarditis experimental infection in young piglets: a potential animal model to study viral myocarditis. Vet Res. 2006;37:15–23.
112. Billinis C, Paschaleri-Papadopoulou E, Psychas V, Vlemmas J, Leonidis S, Koubmati M, et al. Persistence of encephalomyocarditis virus (EMCV) infection in piglets. Vet Microbiol. 1999;70:171–7.
113. Jeoung HY, Lee WH, Jeong W, Shin BH, Choi HW, Lee HS, et al. Immunogenicity and safety of virus-like particle of the porcine encephalomyocarditis virus in pig. Virol J. 2011;8:170.
114. Pope CR. Chicken anemia agent. Vet Immunol Immunopathol. 1991;30:51–65.
115. Koch G, van Roozelaar DJ, Verschuuren CA, van der El Al, Noteborn MH. Immunogenic and protective properties of chicken anemia virus proteins expressed by baculovirus. Vaccine. 1995;13:763–70.
procedures on the integrity and immunogenicity of porcine parvovirus-like particles. Vaccine. 2000;19:726–34.
151. Marek M, van Oers MM, Devaraj FF, Vlak JM, Merten OW. Engineering of baculovirus vectors for the manufacture of virion-free biopharmaceuticals. Biotechnol Bioeng. 2011;108:1056–67.
152. Meeusen EN, Walker J, Peters A, Pastoret PP, Jungersen G. Current status of veterinary vaccines. Clin Microbiol Rev. 2007;20:489–510.
153. Kratz PA, Bottcher B, Nassal M. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc Natl Acad Sci U S A. 1999;96:1915–20.
154. Caballero S, Guix S, Ribes E, Bosch A, Pinto RM. Structural requirements of astrovirus virus-like particles assembled in insect cells. J Virol. 2004;78:13285–92.
155. Charpilienne A, Nejmeddine M, Berois M, Perez N, Neumann E, Hewat E, et al. Individual rotavirus-like particles containing 120 molecules of fluorescent protein are visible in living cells. J Biol Chem. 2001;276:29361–7.
156. Neiryck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med. 1999;5:1157–63.
157. Jeoung HY, Lee WH, Jeong W, Ko YJ, Choi CU, An DJ. Immune responses and expression of the virus-like particle antigen of the porcine encephalomyocarditis virus. Res Vet Sci. 2010;89:295–300.
158. Istrate C, Hinkula J, Charpilienne A, Poncet D, Cohen J, Svensson L, et al. Parenteral administration of RF 8-2/6/7 rotavirus-like particles in a one-dose regimen induce protective immunity in mice. Vaccine. 2008;26:4594–601.
159. Conner ME, Zarley CD, Hu B, Parsons S, Drabinski D, Greiner S, et al. Virus-like particles as a rotavirus subunit vaccine. J Infect Dis. 1996;174 Suppl. 1:S88–92.
160. Peacey M, Wilson S, Baird MA, Ward VK. Versatile RHDV virus-like particles: incorporation of antigens by genetic modification and chemical conjugation. Biotechnol Bioeng. 2007;98:968–77.